JP2022509372A5 - - Google Patents

Info

Publication number
JP2022509372A5
JP2022509372A5 JP2021547670A JP2021547670A JP2022509372A5 JP 2022509372 A5 JP2022509372 A5 JP 2022509372A5 JP 2021547670 A JP2021547670 A JP 2021547670A JP 2021547670 A JP2021547670 A JP 2021547670A JP 2022509372 A5 JP2022509372 A5 JP 2022509372A5
Authority
JP
Japan
Prior art keywords
antibody
sequence
variable domain
amino acid
antibody variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021547670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/058286 external-priority patent/WO2020092202A2/en
Publication of JP2022509372A publication Critical patent/JP2022509372A/ja
Publication of JP2022509372A5 publication Critical patent/JP2022509372A5/ja
Priority to JP2024176055A priority Critical patent/JP2024177499A/ja
Pending legal-status Critical Current

Links

JP2021547670A 2018-10-29 2019-10-28 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント Pending JP2022509372A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024176055A JP2024177499A (ja) 2018-10-29 2024-10-07 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751962P 2018-10-29 2018-10-29
US62/751,962 2018-10-29
PCT/US2019/058286 WO2020092202A2 (en) 2018-10-29 2019-10-28 Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024176055A Division JP2024177499A (ja) 2018-10-29 2024-10-07 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント

Publications (2)

Publication Number Publication Date
JP2022509372A JP2022509372A (ja) 2022-01-20
JP2022509372A5 true JP2022509372A5 (https=) 2022-11-01

Family

ID=68582454

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547670A Pending JP2022509372A (ja) 2018-10-29 2019-10-28 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント
JP2024176055A Pending JP2024177499A (ja) 2018-10-29 2024-10-07 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024176055A Pending JP2024177499A (ja) 2018-10-29 2024-10-07 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント

Country Status (13)

Country Link
US (1) US20220089704A1 (https=)
EP (1) EP3873934A2 (https=)
JP (2) JP2022509372A (https=)
KR (1) KR20210111242A (https=)
CN (1) CN113508135A (https=)
AU (1) AU2019371814A1 (https=)
BR (1) BR112021008105A2 (https=)
CA (1) CA3117409A1 (https=)
EA (1) EA202191179A1 (https=)
IL (1) IL282677A (https=)
MA (1) MA54070A (https=)
MX (1) MX2021004772A (https=)
WO (1) WO2020092202A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2022023559A1 (en) * 2020-07-31 2022-02-03 Curevac Ag Nucleic acid encoded antibody mixtures
US20250222129A1 (en) * 2022-03-21 2025-07-10 National Research Council Of Canada Lipid Based Nanoparticles for Targeted Gene Delivery to the Brain
CN116650660B (zh) * 2023-07-27 2023-11-03 上海偌妥生物科技有限公司 制备抗体偶联小分子药物的方法及其应用
CN119735674B (zh) * 2024-12-06 2026-01-16 合肥综合性国家科学中心大健康研究院 抗vmat2的抗体或其抗原结合片段及其组合物和应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2441903C (en) * 2000-05-26 2012-07-31 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
WO2005037867A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
MEP35408A (en) 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
EP3470072A1 (en) 2005-06-23 2019-04-17 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing
CA2620351C (en) 2005-08-31 2015-04-21 Universite Laval Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
JP2010536341A (ja) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
CA2729961C (en) * 2008-07-09 2018-05-01 Biogen Idec Ma Inc. Li113, li62 variant co2, anti-lingo antibodies
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
KR101813727B1 (ko) 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
KR20130020765A (ko) 2010-02-16 2013-02-28 메디뮨 엘엘씨 Ｈｓａ-관련 조성물 및 사용방법
NZ601117A (en) * 2010-03-03 2014-06-27 Boehringer Ingelheim Int Biparatopic abeta binding polypeptides
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
CA2813493C (en) 2010-10-11 2019-07-09 University Of Zurich Human anti-tau antibodies
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
AU2011343161B2 (en) 2010-12-17 2017-02-02 Neurimmune Holding Ag Human anti-SOD1 antibodies
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CN103379915A (zh) 2011-02-15 2013-10-30 米迪缪尼有限公司 Hsa相关组合物及使用方法
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
US9587014B2 (en) 2011-10-28 2017-03-07 Biogen International Neuroscience Gmbh TDP-43 specific binding molecules
US9676849B2 (en) * 2012-01-10 2017-06-13 Biogen Ma Inc. Enhancement of transport of therapeutic molecules across the blood brain barrier
JP6355563B2 (ja) 2012-02-27 2018-07-11 アムニクス オペレーティング インコーポレイテッド Ｘｔｅｎ共役組成物およびそれを製造する方法
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
CA2896066C (en) 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US20160033523A1 (en) 2013-02-16 2016-02-04 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
KR102042174B1 (ko) * 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
WO2014179657A1 (en) 2013-05-03 2014-11-06 Eleven Biotherapeutics, Inc. Albumin variants binding to fcrn
SG10201902850TA (en) 2014-09-30 2019-04-29 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
ES2924282T3 (es) * 2014-12-19 2022-10-05 Medimmune Ltd Moléculas de transporte a través de la barrera hematoencefálica y usos de las mismas
US10654917B2 (en) * 2015-01-29 2020-05-19 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
WO2017106462A1 (en) 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
BR112019000220A2 (pt) * 2016-07-06 2019-04-24 National Research Council Of Canada anticorpos humanizados que transmigram a barreira hematoencefálica e usos dos mesmos
WO2018109663A1 (en) * 2016-12-12 2018-06-21 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
WO2018138709A1 (en) * 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
CA3059938A1 (en) * 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof

Similar Documents

Publication Publication Date Title
JP2022509372A5 (https=)
CN104105708B (zh) PDGF受体β结合多肽
JP6952827B2 (ja) 血液脳関門輸送分子およびそれらの使用
US11286312B2 (en) Multispecific antibodies
JP2022518392A5 (https=)
BR112020004543A2 (pt) proteínas de ligação ativadas condicionalmente restritas
JP2022515424A (ja) 突然変異ｆａｂドメインを有する多重特異性結合タンパク質
JP7458327B2 (ja) 血液脳関門移動化合物及びその使用
BR122020025858B1 (pt) Complexo de proteína biespecífico e composição compreendendo o mesmo
EP3129051A1 (en) Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
KR101344611B1 (ko) 인간 ｔｗｅａｋ 에 대한 항체 및 이의 용도
CN111356701A (zh) 抗α-突触核蛋白抗体及其用途
JP2021512159A5 (https=)
JP2022509372A (ja) 血液脳関門輸送の促進のためのヒト化され安定化されたｆｃ５バリアント
KR20240107202A (ko) 항-트랜스페린 수용체 항체 및 이의 용도
CN118103359A (zh) 一种艾日布林衍生物的制备方法
EP3551666A1 (en) Antibody variants transmigrating the blood-brain barrier and uses thereof
TW202041534A (zh) 基於假Fab的多特異性結合蛋白
CA2463616C (en) Affinity enhancement agents
JP2012506237A (ja) Ｄｃ−ｓｉｇｎに対する結合特異性をもつリガンド
JP2019527238A (ja) 薬物送達のための抗体融合タンパク質
EP3674316A1 (en) Multispecific binding proteins with mutant fab domains
EP4480965A1 (en) Transferrin receptor-binding molecules, conjugates thereof and their uses to prevent or treat cns diseases
EP4563586A1 (en) New inhibitors of lrrk2/pp1 interaction
RU2827657C2 (ru) Мультиспецифические связывающие белки с мутантными доменами fab